Author:
Lee Ivan T,Cosgrove Catherine A,Moore Patrick,Bethune Claire,Nally Rhiannon,Bula Marcin,Kalra Philip A,Clark Rebecca,Dargan Paul I,Boffito Marta,Sheridan Ray,Moran Ed,Darton Thomas C,Burns Fiona,Saralaya Dinesh,Duncan Christopher J A,Lillie Patrick J,San Francisco Ramos Alberto,Galiza Eva P,Heath Paul T,Girard Bethany,Parker Christy,Rust Dondi,Mehta Shraddha,de Windt Elizabeth,Sutherland Andrea,Tomassini Joanne E,Dutko Frank J,Chalkias Spyros,Deng Weiping,Chen Xing,Feng Jing,Tracy LaRee,Zhou Honghong,Miller Jacqueline M,Das Rituparna,Bethune Claire,Boffito Marta,Browne Duncan,Bula Marcin,Burns Fiona,Chadwick David,Clark Rebecca,Cosgrove Catherine A.,Dargan Paul I.,Darton Thomas C.,Duncan Christopher J.A.,Emmett Stevan,Galiza Eva P.,Galloway James,Heath Paul T.,Jones Lucy,Kalra Philip A.,Kaminski Rachel,Lazarus Rajeka,Lillie Patrick J.,Moore Patrick,Moran Ed,Nally Rhiannon,Palfreeman Adrian,Ramos Alberto San Francisco,Rampling Tommy,Sahdev Anju,Saralaya Dinesh,Sheridan Ray,Soiza Roy
Funder
National Institute for Health and Care Research
Department of Health and Social Care
Reference17 articles.
1. A bivalent omicron-containing booster vaccine against COVID-19;Chalkias;N Engl J Med,2022
2. Safety and immunogenicity of omicron BA.4/BA.5 bivalent vaccine against COVID-19;Chalkias;medRxiv,2022
3. Chalkias S, Harper C, Vrbicky K, et al. Three-month antibody persistence of a bivalent omicron-containing booster vaccine against COVID-19. Nat Commun (in press).
4. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection—increasing community access to testing program, United States, September–November 2022;Link-Gelles;MMWR Morb Mortal Wkly Rep,2022
5. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated hospitalization among immunocompetent adults aged ≥65 years—IVY network, 18 states, September 8–November 30, 2022;Surie;MMWR Morb Mortal Wkly Rep,2022